Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Bispecific Antibodies and CAR T-Cell Therapies Continue to Reshape Myeloma Treatment Landscape

November 22nd 2024

Syed Abbas Ali, MBBS, discusses how CAR T-cell therapies and bispecific antibodies have altered treatment in relapsed/refractory multiple myeloma.

Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH

November 21st 2024

Dr Campos discusses clinical implications from the gynecologic cancer cohorts of DESTINY-PanTumor02 and considerations for managing adverse effects in patients receiving T-DXd.

Liquid Biopsies, ctDNA Could Help Guide Gastrointestinal Cancer Management

November 19th 2024

Tanios S. Bekaii-Saab, MD, discusses the role of liquid biopsies and ctDNA in gastrointestinal cancers.

Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer

November 17th 2024

Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.

Research Aims to Expand RAS Inhibitor Options in Pancreatic Cancer

November 15th 2024

Brandon G. Smaglo, MD, FACP, discusses ongoing research with novel RAS inhibitors in pancreatic cancer.

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

November 14th 2024

Dr Ajani discusses the FDA approval of frontline zolbetuximab plus chemo for unresectable or metastatic, HER2–, CLDN18.2+ gastric or GEJ adenocarcinoma.

Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma

November 14th 2024

Alex F. Herrera, MD, discusses long-term data from nivolumab plus AVD in advanced-stage Hodgkin lymphoma.

Retrospective Data Show Pacritinib Improves TSS in Transfusion-Dependent Myelofibrosis

November 13th 2024

A retrospective study showed pacritinib improved symptoms in transfusion-dependent myelofibrosis.

IBI354 Shows Efficacy and Safety in HER2+ and HER2-Low Advanced Breast Cancer

November 13th 2024

IBI354 showed favorable safety and efficacy in patients with advanced HER2-positive and HER2-low breast cancer.

Refined Definition of Platinum Resistance, Novel ADCs Could Bring More Changes to Ovarian Cancer Treatment

November 12th 2024

Kathleen N. Moore, MD, MS, discusses the evolving treatment landscape of platinum-resistant ovarian cancer.

Preoperative Radiotherapy Plus Perioperative Chemo Improves pCR Rate but Not Survival in Resectable Gastric/GEJ Cancer

November 5th 2024

Trevor Leong, MBBS, MD, FRANZCR, discusses findings from the TOPGEAR trial assessing perioperative chemoradiotherapy in gastric/GEJ cancer.

Neoadjuvant SHR-A1811 Plus Pyrotinib Shows Preliminary Efficacy, Safety in HER2+ Breast Cancer

November 4th 2024

Neoadjuvant SHR-A1811 plus pyrotinib generated response and had a manageable safety profile in HER2+ breast cancer.

Indirect Comparison Shows Superiority of Cilta-Cel vs SOC Regimens in Lenalidomide-Refractory Myeloma

November 1st 2024

Michel Delforge, MD, PhD, discusses an indirect comparison of cilta-cel vs standard-of-care regimens in lenalidomide-refractory multiple myeloma.

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

October 30th 2024

In this Oncology Unplugged episode, Dr. Chandler Park and Dr. Vivek Subbiah discuss advancements in precision oncology, next-gen sequencing, and tissue-agnostic therapies.

Patients Characteristics, Sequencing Considerations Are Vital in Prostate Cancer Management

October 30th 2024

Bradley C. Carthon, MD, PhD, discusses recent data and the evolving treatment landscape in prostate cancer.

RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors

October 28th 2024

The first-in-class CDK8/19 inhibitor RVU120 demonstrated early signs of clinical activity in patients with relapsed/refractory metastatic or advanced solid tumors.

Bispecific Antibodies, Novel Combinations Highlight Continued Treatment Evolution in Follicular Lymphoma

October 26th 2024

David C. Fisher, MD, discusses the evolving therapeutic landscape in follicular lymphoma.

First-Line Ivonescimab Plus Chemotherapy Demonstrates Efficacy in Advanced TNBC

October 24th 2024

Xiaojia Wang, MD, discusses findings for ivonescimab plus chemotherapy in metastatic triple-negative breast cancer.

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

October 24th 2024

Hear Alan P. Venook, MD, discuss recent updates to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for gastrointestinal cancers.

177Lu-PNT2002 Boosts rPFS in PSMA+ mCRPC Following ARPI Progression

October 23rd 2024

177Lu-PNT2002 improved radiographic progression-free survival in PSMA-positive mCRPC after progression on an ARPI.